

# Primary Congenital Intestinal Lymphangiectasia: A Case Report

Tatiana Díaz-Gómez,<sup>1\*</sup> Pablo Sempértegui-Cárdenas,<sup>2</sup> Ana Tinoco-Ochoa.<sup>2</sup>

## OPEN ACCESS

### Citation:

Díaz-Gómez T, Sempértegui-Cárdenas P, Tinoco-Ochoa A. Primary Congenital Intestinal Lymphangiectasia: A Case Report. *Revista Colomb. Gastroenterol.* 2024;39(2):219-223. <https://doi.org/10.22516/25007440.1082>

<sup>1</sup> Third-Year Resident of the Pediatrics Postgraduate Program. Universidad de Cuenca, Hospital Vicente Corral Moscoso. Cuenca, Ecuador.

<sup>2</sup> Vicente Corral Moscoso Hospital, Department of Pediatrics. Cuenca, Ecuador.

\*Correspondence: Tatiana Díaz-Gómez. [tatidi2404@hotmail.com](mailto:tatidi2404@hotmail.com)

Received: 12/05/2023  
Accepted: 27/07/2023



## Abstract

Primary intestinal lymphangiectasia (PIL) is a rare disease that was discovered in 1961 by Waldmann et al., who first described the concept of intestinal lymphangiectasia. PIL is manifested by large and dilated intestinal lymphatic vessels that lead to the loss of lymphatic fluid to the intestinal lumen, including severe hypoalbuminemia and, consequently, generalized edema. The etiology of PIL is unknown; however, several genes are involved in the development of the lymphatic system. The case of a two-month-old patient with a prenatal diagnosis of ascites on third-trimester ultrasound was presented. The patient was born with rapidly progressive ascites and showed an endoscopic study with evidence of snowflake images and histology compatible with intestinal lymphangiectasia. The patient remained on octreotide infusion at baseline and subsequently with refractory ascites the dose was increased. Several evacuatory paracentesis were performed and he remained on enteral nutrition based on an extensively hydrolyzed formula with a 54% contribution of medium chain triglycerides (MCTs) and parenteral nutrition (PN). Subsequently, the patient was switched to a subcutaneous infusion of octreotide, which allowed hospital discharge and adequate outpatient follow-up with a favorable evolution.

## Keywords

Ascites, intestinal lymphangiectasia, octreotide, children.

## INTRODUCTION

Primary intestinal lymphangiectasia (PIL) is a rare disease characterized by the presence of large, extensive intestinal lymphatic vessels, leading to the loss of lymphatic fluid into the intestinal lumen. This condition results in severe hypoalbuminemia and consequently generalized edema<sup>(1)</sup>. PIL was first described in 1961 by Waldmann, who observed varying degrees of lymphatic vessel dilation in 18 patients<sup>(2)</sup>. The etiology of PIL remains unknown; however, several genes, including VEGFR3, PROX1, FOXC2,

and SOX18, are implicated in the development of the lymphatic system<sup>(3)</sup>.

PIL can be suspected at birth or during pregnancy based on ultrasound imaging, which can detect fetal ascites or lower limb lymphedema<sup>(2)</sup>. In a child with symptoms suggestive of PIL, routine tests typically indicate hypoalbuminemia, lymphopenia, and hypogammaglobulinemia. The diagnosis is confirmed through endoscopy, which reveals the characteristic snowflake appearance of the affected duodenal mucosa, and histological examination of biopsies showing lymphatic vessel dilation<sup>(4)</sup>.

The primary treatment strategy for PIL involves dietary modification, specifically a low-fat diet supplemented with medium-chain triglycerides (MCT)<sup>(2)</sup>. When dietary measures are insufficient, dietary supplements or enteral nutrition based on fat-free formulas or formulas with MCTs<sup>(5)</sup> as the main lipid content are utilized<sup>(5)</sup>. In cases where dietary interventions fail, additional options can be considered, either alone or in combination with a low-fat diet and MCT supplementation<sup>(2)</sup>. Second-line therapies include surgical interventions (ranging from laparoscopic resection to major surgery such as *duodenopancreatectomy*), radiological interventions, and medications. The choice of treatment depends on the extent of the disease<sup>(6)</sup>. The prognosis of PIL can be severe and potentially fatal, particularly when malignant complications (such as lymphoma) or pleural or pericardial effusions occur<sup>(2)</sup>.

## CASE PRESENTATION

The patient is a two-month-old girl with a prenatal diagnosis of ascites identified on a third-trimester ultrasound, which led to a planned cesarean section. She was born weighing 3500 grams and was discharged with furosemide and instructions for exclusive breastfeeding. At one and a half months of age, she presented with an increased abdominal circumference and had five episodes of food vomiting, leading to her hospitalization.

On physical examination, the following data were recorded: weight: 6.8 kg, height: 60 cm, weight/height index (+2SD) unreliable due to ascites, mid-upper arm circumference (-3SD) indicating severe malnutrition, and abdominal circumference: 53 cm. The abdomen displayed a collateral venous network and was globular, tense, with a positive fluid wave and crescent-shaped dullness. The remainder of the examination was apparently normal.

Paraclinical test results were as follows: white blood cells: 4900/ $\mu$ L, neutrophils: 41.8%, lymphocytes: 39.9%, hemoglobin: 11 g/dL, platelets: 531,000, fibrinogen: 351 mg/dL, total proteins: 4.9 g/dL, albumin: 3.4 g/dL, globulin: 1.5 g/dL, urea: 9.1 mg/dL, creatinine: 0.21 mg/dL, cholesterol: 138.9 mg/dL, triglycerides: 5512.6 mg/dL, C-reactive protein (CRP): 0.28 mg/dL, immunoglobulin A (IgA): 0.2 g/L, immunoglobulin G (IgG): 2.2 g/L, immunoglobulin M (IgM): 0.4 g/L, immunoglobulin E (IgE): 3.4 IU/mL, alpha-fetoprotein: 434 IU/mL, carcinoembryonic antigen: 1.5 ng/mL, CA 125: 568.1 IU/mL, CA 15-3: 6 U/mL, CA 19-9: 10 U/mL, fecal fats: positive. The ascitic fluid study showed a milky white appearance, albumin: 0.8 g/dL, amylase: 16 U/L, glucose: 133.5 mg/dL, proteins: 2.7 g/dL, lactate dehydrogenase (LDH): 442 U/L, white blood cell count: 0.209 cells/mL, lymphocytes


79%, neutrophils: 21%, ascitic fluid culture: negative, acid-fast bacilli (AFB) and GeneXpert in ascitic fluid: negative.

Imaging studies included a chest-abdominal X-ray, which revealed abundant free fluid. Both the abdominal ultrasound and the triphasic abdominal computed tomography (CT) scan (**Figure 1**) indicated marked ascites. Upper gastrointestinal endoscopy showed snowflake-like images in the first, second, and third portions of the duodenum (**Figures 2A and B**). Duodenal biopsy revealed villi with a preserved crypt-villus ratio (greater than 2.5/1), and no increase in intraepithelial lymphocytes (less than 30%) was observed with routine techniques. Slightly dilated mucosal and submucosal lymphatic vessels surrounded by scant lymphoplasmacytic infiltrate were noted in the lamina propria of some villi, without macrophages suggesting xanthomatous lesions. Immunohistochemical staining with podoplanin (D-240) highlighted lymphatic vascular structures in isolated villi, findings consistent with focal duodenal lymphangiectasia (**Figures 3A and B**).




**Figure 1.** Triphasic abdominal CT scan showing homogeneous parenchyma of the liver and spleen, pancreas with a normal tissue attenuation pattern, normal kidneys, spontaneous ascites, bilateral posterobasal subsegmental pulmonary atelectasis, and no identifiable tumors. Source: Patient's medical records.

Upon admission, the patient received an intravenous dose of albumin at 1 g/kg and was started on prophylactic cefazolin before the diagnostic and therapeutic paracentesis. A milky fluid of 370 mL was obtained (**Figure 4**), prompting



**Figure 2.** Endoscopic images of the first, second, and third portions of the duodenum displaying white speckling with a snowflake appearance that does not disappear with pressure washing. Pathological findings are indicated by blue arrows. Source: Patient's medical records.



**Figure 3. A.** Duodenal mucosa. **B.** Histological sections of duodenal biopsy with podoplanin (D2-40) immunohistochemical staining highlighting lymphatic vascular structures in isolated villi. Source: Patient's medical records.

the initiation of octreotide infusion at 1  $\mu\text{g}/\text{kg}/\text{h}$  along with total parenteral nutrition (TPN). This regimen was maintained initially and later increased to 3  $\mu\text{g}/\text{kg}/\text{h}$  due to refractory ascites. Several evacuative paracenteses were performed, draining volumes up to 900 mL, with concurrent albumin administration for replacement. Due to the unavailability of formulas with exclusive medium-chain triglycerides (MCT) in the country, an extensively hydrolyzed formula containing MCT was used. Subsequently, the octreotide infusion was switched to subcutaneous administration at 100  $\mu\text{g}$  every eight hours, which allowed the discontinuation of parenteral nutrition after 25 days of hospitalization. On day 26, the patient was discharged with an abdominal circumference of 38 cm and treatment that included an extensively hydrolyzed formula, MCT, subcutaneous octreotide, spironolactone, fat-soluble vitamins, and folic acid. During follow-up in the outpatient service,

she required hospitalization once more for a therapeutic paracentesis, but she continued to show favorable progress.

## DISCUSSION

PIL is a rare disease, and the prevalence of its clinically manifest form is unknown due to the presence of asymptomatic cases. Few cases have been reported in Latin America, and none in Ecuador. In children, it is generally diagnosed before the age of three but can present later in childhood or even in adulthood<sup>(2)</sup>.

The main clinical manifestation is peripheral edema of varying degrees, which is usually symmetrical. However, moderate serous effusions such as pleural effusion, pericarditis, or chylous ascites are common and can be life-threatening in severe forms<sup>(2)</sup>. In this case, the patient presented with ascites detected on ultrasound during pregnancy,



**Figure 4.** Paracentesis showing the extraction of milky ascitic fluid. Source: Patient's medical records.

which was already a warning sign for appropriate management at birth. Unfortunately, adequate management was not initiated until she was one month old, by which time the ascites had become severe.

Although several methods have been proposed to investigate PIL, none can replace the histological examination of biopsies for confirming the diagnosis<sup>(2)</sup>. Routine imaging tests at the onset, such as abdominal ultrasound and computed tomography (CT), can typically identify diffuse thickening of the small intestine wall and edema, which are consequences of dilated lymphatic vessels within the villi<sup>(2)</sup>.

Diet modification is the cornerstone of PIL treatment, involving a high-protein diet (2 g/kg/day) and low-fat content (< 25 g/day). The fat component should consist of more than 90% MCTs and short-chain triglycerides SCTs because these components are transported directly to the portal circulation instead of the lymphatic system, thereby decreasing intestinal lymphatic flow and preventing the rupture of lymphatic vessels with the resultant loss of proteins and T cells<sup>(2,6)</sup>. TPN allows for digestive rest and a reduction in splanchnic and subsequently chylous flow. TPN is not recommended as an initial nutritional support measure but is an option for patients who cannot tolerate or have contraindications to oral feeding, do not respond to dietary treatment, have an underlying disease requiring more aggressive nutritional therapy, or are malnourished<sup>(5)</sup>.

Other treatment options depend on the extent of the disease. Focal segmental PIL refractory to dietary therapy can be treated by intestinal resection or radiological embolization.

Diffuse intestinal lymphangiectasia and extensive lymphangiectasia require treatment with drugs such as octreotide, propranolol, and tranexamic acid<sup>(6)</sup>.

Octreotide is a somatostatin analogue that decreases splanchnic blood flow, intestinal motility, and triglyceride absorption. Therefore, it can be optimally used in patients with intestinal lymphatic vessel involvement only<sup>(6)</sup>. Complete resolution of chylous effusion has been observed after initiating octreotide therapy in newborns<sup>(7)</sup>. An induction therapy with a subcutaneous injection of 1 to 10 µg/kg/dose twice daily for two weeks is recommended, followed by the same dose injected subcutaneously at four-week intervals as maintenance therapy<sup>(6)</sup>. However, in our patient, we initially opted for an octreotide infusion, which has shown good response in cases of congenital chylothorax, before transitioning to subcutaneous administration at doses up to 40 µg/kg/day<sup>(8)</sup>. Albumin infusion is a symptomatic treatment proposed for patients with significant ascites<sup>(9)</sup> or severe lower limb edema, but its effectiveness is transient due to persistent lymph leakage into the intestinal lumen<sup>(2)</sup>.

Other therapeutic options include propranolol, which appears to have a therapeutic effect on the endothelium of lymphatic vessels<sup>(6)</sup>. Tranexamic acid has demonstrated utility, as intestinal protein loss can occur during increased fibrinolytic activity<sup>(10)</sup>.

## CONCLUSIONS

- PIL is a rare disease characterized by large, extensive intestinal lymphatic vessels leading to lymphatic fluid loss into the intestinal lumen.
- The diagnosis of PIL is confirmed by histological examination of intestinal biopsy samples.
- Diet modification is the cornerstone of PIL treatment.

## RECOMMENDATIONS

Healthcare professionals should be made aware of the suggestive symptoms of this rare disease to facilitate early and appropriate intervention, thereby improving the quality of life for these patients. No other cases of PIL have been reported in Ecuador, making it important to note that the treatment was successful despite local challenges.

## Conflict of Interest

The authors declare no conflict of interest.

## Funding Sources

This research did not receive any specific grants from public, commercial, or non-profit funding agencies.

## REFERENCES

---

1. Altın Z, Atabay Y, Özer S, Karakoyun M, Ekmekçi S, Yürekli EY, et al. Primary intestinal lymphangiectasia and a review of the current literature. *Turk J Gastroenterol.* 2018;29(6):714-716.  
<https://doi.org/10.5152/tjg.2018.18596>
2. Vignes S, Bellanger J. Primary intestinal lymphangiectasia (Waldmann's disease). *Rev Med Interne.* 2018;39(7):580-585.  
<https://doi.org/10.1016/j.revmed.2017.07.009>
3. Hokari R, Kitagawa N, Watanabe C, Komoto S, Kurihara C, Okada Y, et al. Changes in regulatory molecules for lymphangiogenesis in intestinal lymphangiectasia with enteric protein loss. *J Gastroenterol Hepatol.* 2008;23(7 Pt 2):e88-95.  
<https://doi.org/10.1111/j.1440-1746.2007.05225.x>
4. Asakura H, Miura SM, Morishita T, Aiso S, Tanaka T, Kitahora T, et al. Endoscopic and histopathological study on primary and secondary intestinal lymphangiectasia. *Dig Dis Sci.* 1981;26(4):312-20.  
<https://doi.org/10.1007/BF01308371>
5. Sánchez P, Rodríguez B, Díaz O, Vázquez N, Murcia C, Rodeiro S. Manejo de la ascitis quilosa y revisión de la literatura. *Nutr Clín Diet Hosp.* 2022;42(1):126-133.
6. Kwon Y, Kim MJ. The Update of Treatment for Primary Intestinal Lymphangiectasia. *Pediatr Gastroenterol Hepatol Nutr.* 2021;24(5):413-422.  
<https://doi.org/10.5223/pghn.2021.24.5.413>
7. Zaki SA, Krishnamurthy MB, Malhotra A. Octreotide Use in Neonates: A Case Series. *Drugs R D.* 2018;18(3):191-198.  
<https://doi.org/10.1007/s40268-018-0237-9>
8. Mas E, Borrelli O, Broekaert I, de-Carpi JM, Dolinsek J, Miele E, et al. Drugs in Focus: Octreotide Use in Children With Gastrointestinal Disorders. *J Pediatr Gastroenterol Nutr.* 2022;74(1):1-6.  
<https://doi.org/10.1097/MPG.0000000000003294>
9. Lopez RN, Day AS. Primary intestinal lymphangiectasia in children: A review. *J Paediatr Child Health.* 2020;56(11):1719-1723.  
<https://doi.org/10.1111/jpc.14837>
10. MacLean JE, Cohen E, Weinstein M. Primary Intestinal and Thoracic Lymphangiectasia: A Response to Antiplasmin Therapy. *Pediatrics.* 2002;109(6):1177-1180.  
<https://doi.org/10.1542/peds.109.6.1177>